Table 1.
Baseline characteristics of the study group according to antithrombotic strategies.
| Clinical Characteristic | All n = 3614 |
OAC n = 3306 |
No OAC n = 308 |
||
|---|---|---|---|---|---|
| APT n = 135 |
Heparin n = 96 | Without any Stroke Prophylaxis n = 77 |
|||
| Age mean (SD), years |
73.6 (10.3) | 73.5 (10.2) | 74.6 (10.3) | 72.6 (10.2) | 77.1 (12.1) |
| <65 | 598 (16.5) | 555 (16.8) | 18 (13.3) | 15 (15.9) | 10 (13.3) |
| 65–74 | 1285 (35.6) | 1188 (35.9) | 46 (34.1) | 39 (40.6) | 24 (31.2) |
| ≥75 | 1731 (47.9) | 1563 (47.3) | 71 (52.6) | 42 (43.8) | 43 (55.8) |
| Female | 1572 (43.5) | 1445 (43.7) | 60 (44.4) | 48 (50.0) | 32 (41.6) |
| Type of atrial fibrillation | |||||
| Paroxysmal | 1723 (47.7) | 1569 (47.5) | 80 (59.3) | 57 (59.4) | 35 (45.5) |
| Persistent | 803 (22.2) | 760 (23.0) | 14 (10.4) | 15 (15.6) | 15 (19.5) |
| Permanent | 1088 (30.1) | 977 (29.6) | 41 (30.4) | 24 (25.0) | 27 (35.1) |
| Medical history | |||||
| Hypertension | 3174 (87.4) | 2918 (88.3) | 112 (83.0) | 83 (86.5) | 63 (81.8) |
| Heart failure | 2529 (70.0) | 2311 (69.9) | 92 (68.1) | 60 (62.5) | 50 (64.9) |
| Vascular disease | 2207 (61.1) | 2005 (60.6) | 112 (83.0) | 64 (66.7) | 42 (54.5) |
| Coronary artery disease | 1979 (54.8) | 1796 (54.3) | 107 (79.3) | 59 (61.5) | 36 (46.8) |
| Previous myocardial infarction | 881 (24.4) | 782 (23.7) | 60 (44.4) | 25 (26.0) | 18 (23.4) |
| Peripheral artery disease | 564 (15.6) | 500 (15.1) | 32 (23.7) | 21 (21.9) | 11 (14.3) |
| Previous stroke/TIA/systemic embolism |
648 (17.9) | 599 (18.1) | 25 (18.5) | 28 (29.2) | 8 (10.4) |
| Diabetes mellitus | 1341 (37.1) | 1218 (36.8) | 53 (39.3) | 35 (36.5) | 32 (41.6) |
| Any previous bleeding | 118 (3.3) | 93 (2.8) | 14 (10.4) | 3 (3.1) | 4 (5.2) |
| Intracranial bleeding | 29 (0.8) | 18 (0.5) | 4 (3.0) | 0 (0.0) | 2 (2.6) |
| Gastrointestinal bleeding | 149 (4.1) | 138 (4.2) | 4 (3.0) | 2 (2.1) | 4 (5.2) |
| Cancer | 186 (5.1) | 149 (4.5) | 13 (9.6) | 8 (8.3) | 5 (6.5) |
| Hemoglobin < 12 g/dL | 872 (24.1) | 751 (22.7) | 45 (33.3) | 25 (26.0) | 30 (39.0) |
| eGFR < 60 mL/min/1.73 m2 | 1731 (47.9) | 1555 (47.0) | 80 (59.3) | 40 (41.7) | 40 (51.9) |
| eGFR < 30 mL/min/1.73 m2 | 255 (6.2) | 178 (5.4) | 24 (17.8) | 11 (11.5) | 12 (15.6) |
| Thromboembolic risk | |||||
| CHA2DS2VASc score mean (SD) |
4.7 (1.6) | 4.7 (1.6) | 4.9 (1.6) | 4.9 (1.6) | 4.5 (1.4) |
| ≥3 | 3331 (92.2) | 3047 (92.2) | 128 (94.8) | 90 (92.8) | 72 (93.5) |
| ≥5 | 1909 (52.8) | 1737 (52.5) | 80 (59.3) | 57 (59.4) | 39 (50.6) |
| Bleeding risk | |||||
| HAS-BLED score mean (SD) |
2.2 (0.8) | 2.2 (0.8) | 2.3 (0.9) | 2.21 (0.9) | 2.2 (0.8) |
| ≥3 | 1208 (33.4) | 1078 (32.6) | 58 (43.0) | 33 (34.4) | 27 (35.1) |
| ≥5 | 13 (0.4) | 11 (0.3) | 1 (0.7) | 0 (0.0) | 0 (0.0) |
| Reason for hospitalization | |||||
| Electrical cardioversion | 796 (22.0) | 784 (23.7) | 5 (3.7) | 21 (21.9) | 4 (5.2) |
| Planned coronarography/PCI | 372 (10.3) | 338 (10.2) | 21 (15.6) | 7 (7.3) | 5 (6.5) |
| CIED implantation/reimplantation | 346 (9.6) | 329 (10.0) | 5 (3.7) | 11 (11.5) | 5 (6.5) |
| Acute coronary syndrome | 240 (6.6) | 197 (6.0) | 38 (28.1) | 7 (7.3) | 4 (5.2) |
| Heart failure | 788 (21.8) | 714 (21.6) | 24 (17.8) | 16 (16.7) | 23 (29.9) |
| Ablation other than AF | 189 (5.2) | 172 (5.2) | 8 (5.9) | 7 (7.3) | 7 (9.1) |
| AF without any procedures | 191 (5.3) | 180 (5.4) | 4 (3.0) | 5 (5.2) | 3 (3.9) |
Abbreviations: AF, atrial fibrillation; APT, antiplatelet drug; CIED, cardiac implantable electronic device; eGFR, estimated glomerular filtration rate; IQR, interquartile range; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; SD, standard deviation; TIA, transient ischemic attack.